Abstract:Alzheimer’s disease is a neurodegenerative disorder with the clinical manifestations of cognitive impairment and reduced abilities of daily living. At present, the most important pathogenesis of AD is neuron apoptosis due to senile plaques caused by amyloid β-protein deposition and neurofibrillary tangle caused by hyperphosphorylation of Tau protein. The drugs launched for the treatment of AD include cholinesterase inhibitors and N-methyl-D-aspartate receptor antagonists. Many drugs for the treatment of AD have entered phase III clinical trials over the past 20 years, including innovative class 1 chemicals in China. This article reviews the clinical studies on drugs for the treatment of AD.
